NICE amends ranibizumab guidance

NICE has overturned its original decision to reject the VEGF-targeting antibody ranibizumab (Lucentis) in the treatment of diabetic macular oedema.

Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY
Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY

In a review of its 2011 guidance, NICE has ruled that ranibizumab can be considered for the treatment of visual impairment due to diabetic macular oedema, providing the eye has a central retinal thickness of 400 micrometers or more at the start of treatment.

The NICE recommendations are made on the proviso that the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

In addition to the revised patient access scheme, the decision was based on an updated clinical analysis of ranibizumab submitted by the manufacturer.

NICE guidance on ranibizumab in diabetic macular oedema

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New secondary prevention approach backed for patients with stable cardiovascular disease

New secondary prevention approach backed for patients with stable cardiovascular disease

NHS prescribers have a new routine option for preventing...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...